Susquehanna International Group
RVNC

Susquehanna International Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Susquehanna International Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,300
Closed -$131K – 13502
2024
Q3 		$131K Sell
25,300
-22,600
-47% -$112K ﹤0.01% 10857
2024
Q2 		$123K Sell
47,900
-201,500
-81% -$688K ﹤0.01% 10874
2024
Q1 		$1.23M Buy
249,400
+135,200
+118% +$800K ﹤0.01% 6404
2023
Q4 		$1M Sell
114,200
-81,100
-42% -$664K ﹤0.01% 6985
2023
Q3 		$2.24M Buy
195,300
+61,100
+46% +$1.17M ﹤0.01% 4902
2023
Q2 		$3.4M Buy
134,200
+30,500
+29% +$950K ﹤0.01% 4165
2023
Q1 		$3.34M Buy
103,700
+28,900
+39% +$901K ﹤0.01% 4109
2022
Q4 		$1.38M Sell
74,800
-76,300
-50% -$1.75M ﹤0.01% 5472
2022
Q3 		$4.08M Buy
151,100
+36,100
+31% +$732K ﹤0.01% 3483
2022
Q2 		$1.59M Sell
115,000
-108,200
-48% -$1.67M ﹤0.01% 5395
2022
Q1 		$4.35M Buy
223,200
+141,400
+173% +$2.14M ﹤0.01% 3874
2021
Q4 		$1.33M Sell
81,800
-9,200
-10% -$153K ﹤0.01% 6502
2021
Q3 		$2.54M Buy
91,000
+26,700
+42% +$762K ﹤0.01% 5323
2021
Q2 		$1.91M Buy
64,300
+6,800
+12% +$196K ﹤0.01% 6029
2021
Q1 		$1.61M Buy
57,500
+26,400
+85% +$730K ﹤0.01% 6459
2020
Q4 		$881K Sell
31,100
-13,700
-31% -$355K ﹤0.01% 7016
2020
Q3 		$1.13M Buy
44,800
+25,900
+137% +$679K ﹤0.01% 5823
2020
Q2 		$462K Sell
18,900
-12,900
-41% -$255K ﹤0.01% 7535
2020
Q1 		$471K Sell
31,800
-45,500
-59% -$941K ﹤0.01% 7075
2019
Q4 		$1.25M Sell
77,300
-7,600
-9% -$118K ﹤0.01% 5093
2019
Q3 		$1.1M Buy
84,900
+10,100
+14% +$124K ﹤0.01% 5489
2019
Q2 		$970K Buy
74,800
+29,000
+63% +$366K ﹤0.01% 5732
2019
Q1 		$722K Buy
+45,800
New +$794K ﹤0.01% 5621
2018
Q4 		– Sell
-47,400
Closed -$1.18M – 10153
2018
Q3 		$1.18M Sell
47,400
-800
-2% -$21.8K ﹤0.01% 4909
2018
Q2 		$1.32M Buy
48,200
+33,700
+232% +$1.01M ﹤0.01% 4788
2018
Q1 		$447K Sell
14,500
-82,300
-85% -$2.65M ﹤0.01% 6864
2017
Q4 		$3.46M Buy
96,800
+79,900
+473% +$2.29M ﹤0.01% 3025
2017
Q3 		$466K Sell
16,900
-9,400
-36% -$228K ﹤0.01% 6638
2017
Q2 		$694K Buy
26,300
+9,500
+57% +$212K ﹤0.01% 6008
2017
Q1 		$349K Buy
+16,800
New +$345K ﹤0.01% 7111
2016
Q4 		– Sell
-10,500
Closed -$170K – 10281
2016
Q3 		$170K Sell
10,500
-6,400
-38% -$92.9K ﹤0.01% 7698
2016
Q2 		$230K Sell
16,900
-21,400
-56% -$378K ﹤0.01% 7376
2016
Q1 		$669K Sell
38,300
-28,100
-42% -$572K ﹤0.01% 5879
2015
Q4 		$2.27M Buy
66,400
+32,600
+96% +$1.13M ﹤0.01% 3783
2015
Q3 		$1.01M Buy
33,800
+25,400
+302% +$771K ﹤0.01% 5744
2015
Q2 		$269K Sell
8,400
-18,400
-69% -$473K ﹤0.01% 8734
2015
Q1 		$556K Buy
+26,800
New +$463K ﹤0.01% 6899

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's RVNC Position: Q1 2025 in Review

Susquehanna International Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 303,073 shares — an estimated $921K sold.

Susquehanna International Group first reported a position in RVNC in Q2 2014 and held it in 32 quarters. The position peaked at $6.44M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Susquehanna International Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 303,073 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $921K.
  • Susquehanna International Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 32 quarters.
  • Susquehanna International Group's Revance Therapeutics, Inc. position peaked at $6.44M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.